Kinetic analysis and optimisation of ¹⁸F-rhPSMA-7.3 PET imaging of prostate cancer.

ABSTRACT:

Purpose

This phase 1 open-label study evaluated the uptake kinetics of a novel theranostic PET radiopharmaceutical, ¹⁸F-rhPSMA-7.3, to optimise its use for imaging of prostate cancer.

Methods

Nine men, three with high-risk localised prostate cancer, three with treatment-naïve hormone-sensitive metastatic disease and three with castration-resistant metastatic disease, underwent dynamic 45-min PET scanning of a target area immediately post-injection of 300 MBq ¹⁸F-rhPSMA-7.3, followed by two whole-body PET/CT scans acquired from 60 and 90 min post-injection. Volumes of interest (VoIs) corresponding to prostate cancer lesions and reference tissues were recorded. Standardised uptake values (SUV) and lesion-to-reference ratios were calculated for 3 time fram

SUBMITTER: Malaspina S 

PROVIDER: S-EPMC8440272 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature